B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis

por Tuscano, Joseph M, Sands, Jacob
Publicado 2009

Checkpoint inhibition in hematologic malignancies

por Tsumura, Aaron, Levis, Daniel, Tuscano, Joseph M.
Publicado 2023

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma

por Kato, Jason, O’Donnell, Robert T., Abuhay, Mastewal, Tuscano, Joseph M.
Publicado 2012

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML

por Jonas, Brian A., Potter, Laura A., Galkin, Maria, Tuscano, Joseph M.
Publicado 2023

A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tum...

por Meckler, Joshua F., Levis, Daniel J., Vang, Daniel P., Tuscano, Joseph M.
Publicado 2023

A Fermented Wheat Germ Extract Contains Protein Components Active against NSCLC Xenografts In Vivo

por Levis, Daniel J., Meckler, Joshua F., O’Donnell, Robert T., Tuscano, Joseph M.
Publicado 2023

Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome

por Pham, Brian, Hoeg, Rasmus, Krishnan, Rajeev, Richman, Carol, Tuscano, Joseph, Abedi, Mehrdad
Publicado 2021

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

por Tuscano, Joseph M., Ma, Yunpeng, Martin, Shiloh M., Kato, Jason, O’Donnell, Robert T.
Publicado 2011

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

por O’Donnell, Robert T., Ma, Yunpeng, McKnight, Hayes C., Pearson, David, Tuscano, Joseph M.
Publicado 2009

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

por O’Donnell, Robert T., Martin, Shiloh M., Ma, Yunpeng, Zamboni, William C., Tuscano, Joseph M.
Publicado 2009

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation

por Barisone, Gustavo A., O’Donnell, Robert T., Ma, Yunpeng, Abuhay, Mastewal W., Lundeberg, Kathleen, Gowda, Sonia, Tuscano, Joseph M.
Publicado 2018

Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies

por Frankel, Paul H., Chung, Vincent, Tuscano, Joseph, Siddiqi, Tanya, Sampath, Sagus, Longmate, Jeffrey, Groshen, Susan, Newman, Edward M.
Publicado 2020

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia

por Tuscano, Joseph, Poh, Christina, Rosenberg, Aaron, Jonas, Brian, Abedi, Mehrdad, Barisone, Gustavo, Schwab, Emily, Lundeberg, Kathleen, Kaesberg, Paul
Publicado 2020

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

por Martin, Shiloh M, Churchill, Eric, McKnight, Hayes, Mahaffey, Christopher M, Ma, Yunpeng, O'Donnell, Robert T, Tuscano, Joseph M
Publicado 2011

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

por Tenold, Matthew E., Moskoff, Benjamin N., Benjamin, David J., Hoeg, Rasmus T., Rosenberg, Aaron S., Abedi, Mehrdad, Tuscano, Joseph M., Jonas, Brian A.
Publicado 2021

Environmental pesticide exposure and non-Hodgkin lymphoma survival: a population-based study

por Poh, Christina, McPherson, John D., Tuscano, Joseph, Li, Qian, Parikh-Patel, Arti, Vogel, Christoph F. A., Cockburn, Myles, Keegan, Theresa
Publicado 2022

A Protective Role of Aryl Hydrocarbon Receptor Repressor in Inflammation and Tumor Growth

por Vogel, Christoph F. A., Ishihara, Yasuhiro, Campbell, Claire E., Kado, Sarah Y., Nguyen-Chi, Aimy, Sweeney, Colleen, Pollet, Marius, Haarmann-Stemmann, Thomas, Tuscano, Joseph M.
Publicado 2019

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia

por Kirschbaum, Mark, Synold, Timothy, Stein, Anthony S., Tuscano, Joseph, Zain, Jasmine M., Popplewell, Leslie, Karanes, Chatchada, O'Donnell, Margaret R., Pulone, Bernadette, Rincon, Amalia, Wright, John, Frankel, Paul, Forman, Stephen J., Newman, Edward M.
Publicado 2011

KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth

por Shimoda, Michiko, Lyu, Yuanzhi, Wang, Kang-Hsin, Kumar, Ashish, Miura, Hiroki, Meckler, Joshua F., Davis, Ryan R., Chantarasrivong, Chanikarn, Izumiya, Chie, Tepper, Clifford G., Nakajima, Ken-ichi, Tuscano, Joseph, Barisone, Gustavo, Izumiya, Yoshihiro
Publicado 2021

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

por Evens, Andrew M., Connors, Joseph M., Younes, Anas, Ansell, Stephen M., Kim, Won Seog, Radford, John, Feldman, Tatyana, Tuscano, Joseph, Savage, Kerry J., Oki, Yasuhiro, Grigg, Andrew, Pocock, Christopher, Dlugosz-Danecka, Monika, Fenton, Keenan, Forero-Torres, Andres, Liu, Rachael, Jolin, Hina, Gautam, Ashish, Gallamini, Andrea
Publicado 2021